Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of INCB161734 Plus Chemotherapy vs Placebo Plus Chemotherapy in KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
jRCT2030260075Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jun 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing INCB161734 plus chemotherapy with Placebo plus chemotherapy (2 arms). Primary endpoints: Overall Survival (OS), Progression-free survival (PFS) by BICR and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
INCB161734
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2030260075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2030260075.